ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Nucleic Acid Therapeutics for "Undruggable" Cancer Targets: Mechanisms, Challenges, and Prospects.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Progress of siRNA Nanomedicines in Modulating the Microenvironment of Triple-Negative Breast Cancer.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Despite significant advances in precision oncology, key oncoproteins such as Ras, MYC, and p53 remain historically difficult to drug. Conventional pharmacologic strategies are fundamentally constrained by their dependency on direct interactions with well-defined structural domains, which these targets lack. Nucleic acid therapeutics offer a transformative paradigm to overcome this central limitation by redirecting pharmacological intervention to the mRNA and genomic levels, thereby operating independently of complex protein structures. In this review, we systematically examine the mechanisms of action and translational progress of diverse nucleic acid modalities, including ASOs, siRNAs, miRNAs, aptamers, and mRNA vaccines against these intractable targets. We comprehensively discuss their mechanisms, such as transcript degradation, translational inhibition, and upstream regulatory interference. Furthermore, we critically analyze the primary translational bottlenecks, specifically focusing on delivery efficiency, safety profiling, and scalable manufacturing, while highlighting recent advances in nanocarrier platforms. Finally, we explore future directions enabled by emerging technologies and computational design. Ultimately, this review highlights how nucleic acid therapeutics represent a paradigm shift, enabling precise regulation of "undruggable" cancer targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.